A POLICY ANALYSIS OF HOW FDA SHOULD REGULATE HUMAN BONE MARROW TRANSPLANTATION

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Austin, Susan A.	en_US
dc.date.accessioned	2012-07-06T22:04:29Z
dc.date.issued	1995	en_US
dc.identifier.citation	A POLICY ANALYSIS OF HOW FDA SHOULD REGULATE HUMAN BONE MARROW TRANSPLANTATION (1995 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965616
dc.description.abstract	Over the past twenty years, physicians have carried out bone marrow transplants with increasing success. As the procedure gains in acceptance and availability over the coming years, our nation will be faced with important policy choices regarding the regulation of bone marrow transplantation.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	national marrow donor program	en
dc.subject	FDA	en
dc.subject	regulation	en
dc.title	A POLICY ANALYSIS OF HOW FDA SHOULD REGULATE HUMAN BONE MARROW TRANSPLANTATION	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T22:04:29Z